Tirzepatide is Eli Lilly's GLP-1/GIP dual agonist, sold as Mounjaro for type-2 diabetes and Zepbound for obesity. The Phase 3 SURMOUNT and SURPASS programs established it as the most potent incretin therapy approved.
SURMOUNT-5, the head-to-head against semaglutide, read out in April 2026 with 21.6% mean weight loss at 72 weeks versus 15.4% for semaglutide; 36.2% of tirzepatide patients hit ≥25% weight loss versus 19.4% on semaglutide. The drug also has FDA approval for moderate-to-severe obstructive sleep apnea via the SURMOUNT-OSA program, and Truveta EHR data presented at OMA 2026 reproduced the head-to-head signal in routine 12-month care.
Like semaglutide, tirzepatide sits on the FDA's April 30, 2026 proposal to exclude branded actives from the 503B bulks list. Stories here track new readouts, the head-to-head economics, and the long compounding fight.
The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026 after a Federal Register-extended deadline from the original June 29 cutoff. The FDA's underlying finding: no clinical need for FDA-registered outsourcing facilities to compound the three GLP-1 molecules from bulk drug substances. Section 503B outsourcing facilities are the FDA-registered large-scale compounding manufacturers (as distinct from state-licensed 503A pharmacies that compound for individual patient prescriptions). Finalization of the proposed rule would close the last legal pathway for large-scale FDA-registered 503B outsourcing facility compounding of the branded GLP-1 molecules, following the December 2024 semaglutide shortage resolution and February 2025 tirzepatide shortage resolution that ended the shortage-based compounding pathway. FDA rulemaking to finalize the exclusion after comment-period close typically takes 3-9 months depending on the volume and substance of received comments. Telehealth platforms including Hims & Hers Health (NYSE: HIMS) and LifeMD have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure. FDA Adverse Event Reporting System (FAERS) data as of the July 2026 safety statement: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide.
A 2026 chemistry study documented that when tirzepatide is compounded with vitamin B12 (a common differentiating additive used by compounding pharmacies to distinguish compounded products from the FDA-approved Mounjaro and Zepbound Eli Lilly formulations), the two substances can chemically bond and form a new molecule not present in the FDA-approved drug product. The finding adds to the accumulating pharmacovigilance case against compounded GLP-1 formulations, which are marketed as bioequivalent to the branded products but frequently contain non-FDA-approved additives whose long-term safety, immunogenicity, and pharmacokinetic profiles have not been characterized in registered clinical trials. Compounding-pharmacy additives often introduce impurities and reaction products that differ from the branded label chemistry. The chemistry-specific finding on tirzepatide + B12 bonding is the type of documented novel-molecule outcome that FDA safety scientists cited in the underlying rationale for the April 30, 2026 proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List. FDA Adverse Event Reporting System (FAERS) data as of July 2026: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide. The FDA 503B comment period on the exclusion closed Thursday July 30, 2026.
The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026. If the FDA finalizes the rule, large-scale FDA-registered 503B outsourcing facilities will no longer be able to legally prepare compounded semaglutide, tirzepatide, or liraglutide once the shortage-based compounding pathway has fully closed. The 503B exclusion is the parallel-track regulatory action to the July 23-24 PCAC vote on the 7 research peptides for the 503A Bulks List. Where 503A operates under state pharmacy board licensure for individual-patient prescriptions, 503B operates under FDA registration for bulk manufacturing at outsourcing facilities. The 503A vote broadened access to 6 of 7 research peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP rejected). The 503B exclusion narrows access for the branded GLP-1 franchise. Both actions require FDA rulemaking to formalize, with typical timelines of 6-18 months from the date the agency decides to act. Telehealth companies including Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure.
Medscape published an emulated randomized trial analysis on Tuesday July 28, 2026 using US insurance claims data from 2018-2023 to test whether patients with stable inflammatory bowel disease (IBD) and comorbid obesity or diabetes benefit from initiating GLP-1 receptor agonist therapy alongside their ongoing IBD treatment. The researchers used a target trial emulation design comparing patients who initiated semaglutide or tirzepatide with patients who did not. Two cohorts were analyzed: Cohort 1 comprised patients on 5-aminosalicylates or no IBD-related therapy; Cohort 2 comprised patients on immunomodulators and/or advanced therapies (biologics or small molecules). Neither cohort showed a lower risk of IBD relapse or improved safety event rates among GLP-1 initiators. The analysis pushes back against the anti-inflammatory hypothesis advanced in preclinical GLP-1 receptor agonist literature (based on animal-model reductions in gut inflammation) and against the informal clinical assumption that IBD patients with obesity or diabetes may derive an anti-inflammatory benefit from initiating GLP-1 therapy. The clinical implication: prescribers should not initiate GLP-1 receptor agonist therapy in stable IBD patients for the purpose of improving IBD outcomes. GLP-1 initiation for obesity or diabetes in this population remains reasonable when the metabolic indication justifies it independently.
The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge Program is 27 days into the July 1, 2026 pilot launch. The program provides eligible Medicare Part D beneficiaries access to specified GLP-1 receptor agonist products at a capped $50 monthly out-of-pocket cost through December 31, 2027. Covered products include all formulations of Wegovy (semaglutide, Novo Nordisk), the KwikPen formulation of Zepbound (tirzepatide, Eli Lilly), and all formulations of Foundayo (orforglipron, Eli Lilly). The program was created through a Most-Favored-Nation (MFN) pricing agreement announced by the Trump administration in Q1 2026 that pairs manufacturer discounts with a fixed patient copay. A KFF (Kaiser Family Foundation) analysis estimates approximately 3.8 million Medicare beneficiaries meet the program's clinical eligibility criteria (obesity with BMI ≥ 30 kg/m² and specific cardiovascular or metabolic comorbidities), representing approximately 8% of the 47.5 million Part D enrollees nationally. CMS has not yet released actual enrollment data from the first program month. The program's actual utilization pattern, adherence rate, and expenditure trajectory will inform whether the pilot is extended past December 31, 2027 or converted to a permanent Medicare Part D obesity benefit.
Australia's Therapeutics Goods Administration (TGA) issued a class-wide product warning update Saturday July 25, 2026 for GLP-1 receptor agonists on non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but severe form of eye disorder that may result in permanent visual impairment including blindness. No treatment has been shown to improve visual acuity outcomes after NAION onset. The label update applies across all five GLP-1 RA products currently marketed in Australia: Trulicity (dulaglutide, Eli Lilly), Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk), Mounjaro (tirzepatide, Eli Lilly), and Saxenda (liraglutide, Novo Nordisk). The Advisory Committee on Medicines concluded that the current evidence supports the signal for semaglutide but not for dulaglutide or tirzepatide. A search of the Australian Database of Adverse Event Notifications (DAEN) found 36 cases of optic ischaemic neuropathy with GLP-1 RAs, including 23 for semaglutide, 10 for tirzepatide, and 3 for liraglutide. Patient guidance advises seeking urgent medical attention for any sudden vision loss including partial loss of vision. The Australian action follows the UK MHRA Drug Safety Update on semaglutide and NAION issued February 5, 2026.
Novo Nordisk announced Friday July 24, 2026 that it has filed for a temporary restraining order (TRO) and preliminary injunction in the US District Court for the District of New Jersey to immediately block Eli Lilly's national Zepbound (tirzepatide) and Mounjaro (tirzepatide) direct-to-consumer advertising campaigns. The escalation comes three business days after Novo's original complaint filed Tuesday July 21 alleging that Lilly's ads rely on outdated Wegovy (semaglutide) dose comparisons that do not account for the newer, higher-dose FDA-approved semaglutide options currently available. Through the TRO and preliminary injunction motions, Novo Nordisk seeks immediate court-ordered removal of the disputed Lilly campaigns pending a full merits ruling on the underlying deceptive-advertising claims. Novo also seeks a permanent injunction requiring Lilly to pull all misleading comparative advertising across platforms and to conduct a corrective advertising campaign. The GLP-1 ad war has moved from network TV pharmacy-facing PBM negotiation into full federal court litigation for the first time in the class's US commercialization history. Court hearing dates on the TRO/preliminary injunction have not yet been reported publicly.
Novo Nordisk (NYSE: NVO) filed a federal lawsuit Tuesday July 21, 2026 against Eli Lilly (NYSE: LLY) alleging that Lilly has run 'deceptive' advertising campaigns for its GLP-1 drugs Zepbound and Mounjaro (both tirzepatide), per STAT News reporting. The Novo complaint reportedly targets marketing claims that make Lilly's tirzepatide franchise appear more effective than the underlying clinical data support relative to Novo's Wegovy and Ozempic (both semaglutide). The lawsuit arrives against a competitive backdrop where Lilly has been extending its US commercial lead in the obesity market: Q1 2026 sales showed Mounjaro at $8.7 billion (up 125% year-over-year) and Zepbound at $4.2 billion (up 80%), while Novo Nordisk faced flat-to-declining semaglutide revenue after March 2026 price cuts, and Lilly overtook Novo in US GLP-1 market share. The SURMOUNT-5 head-to-head Phase 3 trial published earlier in 2026 showed superior efficacy for tirzepatide over semaglutide on weight loss endpoints; Novo's complaint appears to focus on how Lilly extrapolates the SURMOUNT-5 comparative data into consumer-facing advertising. The dispute frames the GLP-1 marketing battlefield ahead of Q2 earnings reports (Lilly August 5, Novo August 6).
US data-analytics firm nference published a real-world evidence analysis this week that compared frailty-related outcomes across three cohorts of US adults 65 and older: nearly 30,000 patients treated with Zepbound (tirzepatide) for obesity, nearly 19,000 receiving non-GLP-1 drugs for type 2 diabetes, and nearly 6,000 who underwent weight-loss surgery. Health records showed progressive declines in muscle mass and function developed in 0.16% of patients across the analysis, malnutrition in 1.6%, dehydration in 3%, and loss of appetite in 4.75%. Lead author Soundararajan's team focused on Zepbound because prior analyses linked tirzepatide with more weight and muscle loss than semaglutide (the active ingredient in Novo Nordisk's Wegovy and Ozempic). The authors said results should not discourage appropriate use of Zepbound or Wegovy in older adults and encouraged closer follow-up of older patients on GLP-1 therapy. The findings arrive as the Medicare GLP-1 Bridge (launched July 1, 2026) expands GLP-1 access to Part D beneficiaries and as prescribers weigh muscle-preservation strategies including selective androgen receptor modulators (SARMs) like Veru's enobosarm and myostatin inhibitors.
A JAMA study led by a Yale researcher, reported by STAT on July 6, had an investigator pose as a patient across 49 websites selling branded or compounded semaglutide or tirzepatide between August and December 2025. Of those, 45 sites (91.8%) issued a prescription, with a median time to prescription of one day or less and often minimal clinical evaluation. The findings sharpen concerns about telehealth prescribing standards as enforcement against compounded GLP-1s tightens.
Sandoz Group announced Monday June 29, 2026 that the FDA accepted two Abbreviated New Drug Applications (ANDAs) from the company for generic versions of Eli Lilly's tirzepatide autoinjectors, covering the type-2-diabetes-labeled Mounjaro and the obesity-labeled Zepbound. The ANDAs cover all approved indications of Mounjaro and Zepbound. If approvals land, Sandoz would launch 'one of the first generic tirzepatide products' in the US, adding real supply-side competition to Lilly's branded product and creating pricing pressure that could reshape the Medicare GLP-1 Bridge economics. The company developed the generic tirzepatide in-house, combining Sandoz's small-molecule and device-development experience with its biosimilar expertise. The ANDA acceptance does not include a projected FDA action date; typical generic-tirzepatide review timelines run 12 to 24 months, putting a potential Sandoz launch window in 2027-2028. The competitive-pressure question is whether generic tirzepatide substitution would apply at the pharmacy counter under the Bridge (the program covers Zepbound KwikPen brand-specifically) or only in the broader Part D market post-Bridge.
The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026 at 11:59 PM ET. The proposal (Federal Register notice May 1, docket 2026-08552) cited 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. The final-comment filers split along expected lines. National Community Pharmacists Association (NCPA) and Alliance for Pharmacy Compounding (APC) argue for retention given continuing patient-access gaps for high-cost branded supply, particularly in rural and underserved markets where Hims & Hers and LifeMD telehealth penetration is lower. Partnership for Safe Medicines and the FDA's CDER drug safety arm support the exclusion, citing more than 455 adverse event reports linked to compounded semaglutide and 320+ reports tied to compounded tirzepatide as of early 2025, with a large fraction involving patient self-dosing errors from multidose vials. The FDA will publish its final determination in the Federal Register within several months of comment closure. Once finalized, large-scale compounded GLP-1 distribution through 503B outsourcing facilities ends; patient-specific 503A compounding may continue under narrow circumstances.
The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026, one day from this Sunday digest. The FDA proposed the exclusion on April 30 via a Federal Register notice published May 1 (docket 2026-08552), citing 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. Once the comment window closes and the FDA finalizes the determination, large-scale compounded GLP-1 distribution through 503B outsourcing facilities effectively ends. Patient-specific compounding through 503A pharmacies may continue under narrow circumstances (drug-shortage triggers, patient-specific clinical needs documented by the prescribing physician), but the bulk-compounding channel that supplied the 2022-2024 shortage-era compounded GLP-1 wave gets formally closed. The Partnership for Safe Medicines and FDA's CDER drug safety arm welcomed the proposal; compounding-pharmacy industry groups (APC, OFA) filed comments arguing for retention given continuing patient-access gaps for high-cost branded supply.
Eli Lilly confirmed in reporting on June 22-23, 2026 that it is halving its planned €2.3 billion (US$2.7 billion) investment at the under-construction Alzey, Rhineland-Palatinate injectable manufacturing site, reducing planned headcount from approximately 1,000 to 500 and pushing the redirected capital toward US sites, most likely Lilly's Pennsylvania facility. The plant produces injectable GLP-1 drugs Mounjaro (tirzepatide for type-2 diabetes), Zepbound (tirzepatide for obesity), and Trulicity (dulaglutide), and is still scheduled to open in 2027 at the reduced capacity. Lilly cited Germany's proposed healthcare reform legislation, particularly a 'dynamic manufacturer rebate' that would automatically lower drug reimbursements as utilization climbs. Boehringer Ingelheim is also slashing planned German investment by at least $1 billion, and Pfizer CEO Albert Bourla has signaled a reassessment. Lilly's CEO David Ricks told the German government the company 'can no longer commit to the full vision for Alzey.' The cut arrives the same week as STAT's retatrutide compassionate-use story, sharpening the contrast between Lilly's expanding US capital deployment and tightening European pricing.
An analysis of 60,000+ Americans with type 2 diabetes, presented at ENDO 2026 by Sainikhil Sontha (Boston University School of Public Health) and published in the Endocrine Society press release stream, found that 40% of GLP-1 users discontinued the medication within 12 months and roughly 60% had stopped by the end of two years. Among those who stopped, 41.5% restarted within a year and 58% within two years. Discontinuation was higher among Medicaid/Medicare beneficiaries, Black patients, and patients with documented nausea or GI side effects (37% of stoppers). Newer-generation tirzepatide users were 41% less likely to discontinue than liraglutide users, and patients whose first GLP-1 was prescribed by an endocrinologist were 10% less likely to stop. The data complement the Cleveland Clinic 8,000-patient real-world finding (March) and the eClinicalMedicine Budini meta-regression on weight-regain trajectory, sharpening the picture of how GLP-1 therapy churn actually unfolds in US insurance-claims populations.
Wegovy and Mounjaro became reimbursable by French Health Insurance effective June 15, 2026 under orders published in the May 28, 2026 Journal Officiel. The patient co-payment rate is 35%, leaving 65% public coverage by the Sécurité Sociale. Eligibility is restricted to specific patient profiles: adults with BMI ≥30 plus a major obesity-associated comorbidity (Wegovy) or with type 2 diabetes (Mounjaro). The decision follows the UK and Switzerland in extending public insurance to GLP-1 obesity therapy, and marks a paradigm shift from 'personal responsibility' toward 'treatable disease' framing in continental European health systems. The change comes ahead of EMA Wegovy pill (oral semaglutide 25 mg) EU launches in H2 2026 following the May 22 CHMP positive opinion.
The two near-term peptide regulatory deadlines moved into the single-digit-week window on June 18. The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closes its 60-day comment window on June 29, after which the agency will weigh comments and issue final rulemaking; once final, the rule blocks 503B outsourcing facilities from bulk-compounding the molecules even under future shortage designation. Separately, requests to make oral presentations at the July 23-24 PCAC peptide-compounding advisory committee close June 30; the committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon for 503A bulk-substances-list inclusion. Written PCAC comments remain open through July 9.
A real-world comparison of tirzepatide and semaglutide for obesity by Venkatakrishnan and colleagues, published in PNAS Nexus on June 16, reported mean body-weight reductions of 14.7% on tirzepatide versus 10.8% on semaglutide at one year. The tirzepatide arm produced close to twice the proportion of 'high responders' (more than 15% body-weight loss) and lower rates of GI events, headache, and fatigue. Female and white patients responded more strongly on either drug than male, black, or Hispanic patients, who were more frequently in the under-5% weight-loss tier. The findings track with SURMOUNT-5's head-to-head trial result and the April 13 OMA Truveta poster but add a new demographic-disparity dimension that should inform real-world treatment selection.